Cargando…
T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern
The progression of the COVID-19 pandemic has led to the emergence of variants of concern (VOC), which may compromise the efficacy of the currently administered vaccines. Antigenic drift can potentially bring about reduced protective T cell immunity and, consequently, more severe disease manifestatio...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878189/ https://www.ncbi.nlm.nih.gov/pubmed/35215940 http://dx.doi.org/10.3390/v14020347 |
_version_ | 1784658602936500224 |
---|---|
author | Cohen, Hila Rotem, Shahar Elia, Uri Bilinsky, Gal Levy, Itzchak Chitlaru, Theodor Bar-Haim, Erez |
author_facet | Cohen, Hila Rotem, Shahar Elia, Uri Bilinsky, Gal Levy, Itzchak Chitlaru, Theodor Bar-Haim, Erez |
author_sort | Cohen, Hila |
collection | PubMed |
description | The progression of the COVID-19 pandemic has led to the emergence of variants of concern (VOC), which may compromise the efficacy of the currently administered vaccines. Antigenic drift can potentially bring about reduced protective T cell immunity and, consequently, more severe disease manifestations. To assess this possibility, the T cell responses to the wild-type Wuhan-1 SARS-CoV-2 ancestral spike protein and the Omicron B.1.1.529 spike protein were compared. Accordingly, peripheral blood mononuclear cells (PBMC) were collected from eight healthy volunteers 4–5 months following a third vaccination with BNT162b2, and stimulated with overlapping peptide libraries representing the spike of either the ancestral or the Omicron SARS-CoV-2 virus variants. Quantification of the specific T cells was carried out by a fluorescent ELISPOT assay, monitoring cells secreting interferon-gamma (IFNg), interleukin-10 (IL-10) and interleukin-4 (IL-4). For all the examined individuals, comparable levels of reactivity to both forms of spike protein were determined. In addition, a dominant Th1 response was observed, manifested mainly by IFNg-secreting cells and only limited numbers of IL-10- and IL-4-secreting cells. The data demonstrate stable T cell activity in response to the emerging Omicron variant in the tested individuals; therefore, the protective immunity to the variant following BNT162b2 vaccination is not significantly affected. |
format | Online Article Text |
id | pubmed-8878189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88781892022-02-26 T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern Cohen, Hila Rotem, Shahar Elia, Uri Bilinsky, Gal Levy, Itzchak Chitlaru, Theodor Bar-Haim, Erez Viruses Brief Report The progression of the COVID-19 pandemic has led to the emergence of variants of concern (VOC), which may compromise the efficacy of the currently administered vaccines. Antigenic drift can potentially bring about reduced protective T cell immunity and, consequently, more severe disease manifestations. To assess this possibility, the T cell responses to the wild-type Wuhan-1 SARS-CoV-2 ancestral spike protein and the Omicron B.1.1.529 spike protein were compared. Accordingly, peripheral blood mononuclear cells (PBMC) were collected from eight healthy volunteers 4–5 months following a third vaccination with BNT162b2, and stimulated with overlapping peptide libraries representing the spike of either the ancestral or the Omicron SARS-CoV-2 virus variants. Quantification of the specific T cells was carried out by a fluorescent ELISPOT assay, monitoring cells secreting interferon-gamma (IFNg), interleukin-10 (IL-10) and interleukin-4 (IL-4). For all the examined individuals, comparable levels of reactivity to both forms of spike protein were determined. In addition, a dominant Th1 response was observed, manifested mainly by IFNg-secreting cells and only limited numbers of IL-10- and IL-4-secreting cells. The data demonstrate stable T cell activity in response to the emerging Omicron variant in the tested individuals; therefore, the protective immunity to the variant following BNT162b2 vaccination is not significantly affected. MDPI 2022-02-08 /pmc/articles/PMC8878189/ /pubmed/35215940 http://dx.doi.org/10.3390/v14020347 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Cohen, Hila Rotem, Shahar Elia, Uri Bilinsky, Gal Levy, Itzchak Chitlaru, Theodor Bar-Haim, Erez T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern |
title | T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern |
title_full | T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern |
title_fullStr | T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern |
title_full_unstemmed | T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern |
title_short | T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern |
title_sort | t cell response following anti-covid-19 bnt162b2 vaccination is maintained against the sars-cov-2 omicron b.1.1.529 variant of concern |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878189/ https://www.ncbi.nlm.nih.gov/pubmed/35215940 http://dx.doi.org/10.3390/v14020347 |
work_keys_str_mv | AT cohenhila tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern AT rotemshahar tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern AT eliauri tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern AT bilinskygal tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern AT levyitzchak tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern AT chitlarutheodor tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern AT barhaimerez tcellresponsefollowinganticovid19bnt162b2vaccinationismaintainedagainstthesarscov2omicronb11529variantofconcern |